Array Biopharma (NASDAQ: ARRY) is an incredibly well positioned tour de force biopharmaceutical company with a strong balance sheet, a vast portfolio of six wholly owned compounds, and a variety of pharma partnered development efforts with AstraZeneca (NYSE: AZN), Celgene (NASDAQ: CELG), InterMune (NASDAQ: ITMN) and Roche (Swiss: RO.SW). President and CEO Robert Conway and [...]

• 310View 1 Comment...http://clsdf.com/2008/02/array-q%e2%80%99ly-report-well-positioned/Array+Q%E2%80%99ly+Report%3A+Well+Positioned%212008-02-06+04%3A44%3A00admin

A few weeks back I posted (here) about the news on Array BioPharma’s (NASDAQ: ARRY) outcome for ARRY-886 and the response Wall Street was having as well as AstraZeneca (NYSE: AZN), Array’s development partner, and Schering Plough (NYSE: SGP) and their competitive oncology product, reactions . My argument was that matching standard of care as [...]

• 290http://clsdf.com/2008/01/array-biopharma-clsdf-reader%e2%80%99s-take/Array+Biopharma%3A+CLSDF+Reader%E2%80%99s+Take2008-01-11+22%3A29%3A00admin